Overview

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to anti-TNF biologic therapy.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Methotrexate
Upadacitinib